Beckman Coulter announces third-quarter results

Beckman Coulter has published its third-quarter financial results

Its revenue during this period reached $822.8 million (497.4 million pounds), a sum that includes the $65.1 million from its recent acquisition of ODS.

This represents in increase of 8.4 per cent on the same quarter of last year.

Reported net earnings were $1.5 million, or $0.02 per fully diluted share.

However, cash instrument sales were found to have declined by 9.4 per cent.

Scott Garrett, chairman, president and chief executive officer of the firm stated: “Clinical diagnostics experienced strong growth in recurring revenue especially in access immunoassay, which again grew more than ten per cent.”

Last month, Beckman Coulter announced that it had devised and launched a new product – the Access sex hormone binding globulin assay – which can be used for the differential diagnosis of conditions of chronic or excessive androgenic activity.

It can also be utilised alongside its Access Testosterone Assay to provide a calculated free androgen index.